Bart J.A. Mertens

Dr. Bart J.A. Mertens

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2011 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
AVAnne Jh Vochteloo
Anne Jh Vochteloo
BBBoudewijn Ls Borger van der Burg
Boudewijn Ls Borger van der Burg
BMBart J.A. Mertens
Bart J.A. Mertens
ANArthur Hp Niggebrugge
Arthur Hp Niggebrugge
MVMark R de Vries
Mark R de Vries
PPPeter Pilot
Peter Pilot
Anemia is more often seen in older patients. As the mean age of hip fracture patients is rising, anemia is common in this population. Allogeneic blood transfusion (ABT) and anemia have been pointed out as possible risk factors for poorer outcome in hip fracture patients.

1 November 2006 in Journal of Computational Biology
Verified
Journal Article
Closed access
BMBart J.A. Mertens
Bart J.A. Mertens
MNM.E. De Noo
M.E. De Noo
RTR.A.E.M. Tollenaar
R.A.E.M. Tollenaar
ADA.M. Deelder
A.M. Deelder
This paper presents an approach to the evaluation and validation of the diagnostic potential of mass spectrometry data in an application on the construction of an "early warning" diagnostic procedure. Our approach is based on a full implementation and application of double cross-validatory calibration and evaluation. It is a key feature of this methodology that we can jointly optimize the classifiers for prediction while simultaneously calculating validated error rates. The methodology leaves the size of the training data nearly intact. We present application to data from a designed experiment in a colon-cancer study. Subsequent to presentation of results from the double cross-validatory analysis, we explore a post-hoc analysis of the calibrated classifiers to identify the markers that drive the classification.

Verified
Journal Article
Open access
PDF file
AHAnouck Huijbers
Anouck Huijbers
BVBerit Velstra
Berit Velstra
TDTim J. A. Dekker
Tim J. A. Dekker
WMWilma Mesker
Wilma Mesker
YBYuri E.M. Van Der Burgt
Yuri E.M. Van Der Burgt
RTRob A. E. M. Tollenaar
Rob A. E. M. Tollenaar
Early diagnosis of cancer is of pivotal importance to reduce disease-related mortality. There is great need for non-invasive screening methods, yet current screening protocols have limited sensitivity and specificity. The use of serum biomarkers to discriminate cancer patients from healthy persons might be a tool to improve screening programs. Mass spectrometry based proteomics is widely applied as a technology for mapping and identifying peptides and proteins in body fluids. One commonly used approach in proteomics is peptide and protein profiling. Here, we present an overview of profiling methods that have the potential for implementation in a clinical setting and in national screening programs.

2 May 2022 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
PDF file
XGXavier Galloo
Xavier Galloo
JSJan Stassen
Jan Stassen
SBSteele C Butcher
Steele C Butcher
MMmaria chiara meucci
maria chiara meucci
MDMarlieke F Dietz
Marlieke F Dietz
VDVictoria Delgado
Victoria Delgado
OBJECTIVES: This study evaluated the prognostic value of staging right heart failure in patients with significant tricuspid regurgitation (TR) undergoing tricuspid valve (TV) surgery. METHODS: Patients with significant TR who underwent TV surgery were divided into 4 right heart failure stages according to the presence of right ventricular (RV) dysfunction and clinical signs of right heart failure: stage 1 was defined as no RV dysfunction and no signs of right heart failure; stage 2 indicated RV dysfunction without signs of right heart failure; stage 3 included RV dysfunction and signs of right heart failure; and stage 4 was defined as RV dysfunction and refractory signs of right heart failure at rest. RESULTS: A total of 278 patients [mean age 64 (12), 49% males] were included, of whom 34 (12%) patients were classified as stages 1 and 2, 141 (51%) as stage 3 and 103 (37%) as stage 4 right heart failure. The majority of patients (91%) had TV surgery concomitant to left-sided valve surgery or coronary artery bypass grafting and 95% underwent TV annuloplasty. Cumulative survival rates were 89%, 78% and 61% at 1 month, 1 year and 5 years, respectively. Stages 1 and 2 and stage 3 were independently associated with better survival compared to stage 4 (hazard ratio: 0.391 [95% confidence interval: 0.186–0.823] and 0.548 [95% confidence interval: 0.369–0.813], respectively). CONCLUSIONS: Patients with significant TR undergoing TV surgery and diagnosed without advanced right heart failure have better survival as compared to patients with right heart failure.


22 September 2017 in JMIR Research Protocols
Verified
Journal Article
Open access
RTRoderick Willem Treskes
Roderick Willem Treskes
LWLouise Anna van Winden
Louise Anna van Winden
NKNicole van Keulen
Nicole van Keulen
DADouwe Ekke Atsma
Douwe Ekke Atsma
Enno Tjeerd Van der VeldeEnno Tjeerd Van der Velde
Enno Tjeerd Van der Velde
MSMartin Jan Schalij
Martin Jan Schalij
Recent evidence suggests that frequent monitoring using smartphone-compatible wearable technologies might improve clinical effectiveness and patient satisfaction of care. The aim of this study is to investigate the clinical effectiveness and patient satisfaction of a smart technology intervention in patients admitted with a ST elevation myocardial infarction (STEMI) or non-ST acute coronary syndrome (NST-ACS). In this single center, open, randomized controlled trial patients who suffered from STEMI or NST-ACS will be randomized 1:1 to an intervention group or control group. Both groups will be followed up to one year after the index event. The intervention group will take daily measurements with a smartphone-compatible electrocardiogram device, blood pressure (BP) monitor, weight scale, and activity tracker. Furthermore, two of four outpatient clinic visits will be replaced by electronic visits (1 and 6 months after index event). The control group will receive regular care, consisting of four outpatient clinic visits (1, 3, 6, and 12 months after index event). All patients will be asked to fill in validated questionnaires about patient satisfaction, quality of life, propensity of medication adherence, and physical activity. The primary outcome of this trial will be percentage of patients with controlled BP. Secondary outcomes include patient satisfaction, health care utilization, major adverse cardiac events, medication adherence, physical activity, quality of life, and percentage of patients in which a sustained arrhythmia is detected. Smart technology could potentially improve care in postmyocardial infarction patients. This trial will investigate whether usage of smart technology can improve clinical- and cost-effectiveness of care. Clinicaltrials.gov NCT02976376; https://clinicaltrials.gov/ct2/show/NCT02976376 (Archived by WebCite at http://www.webcitation.org/6tcvAdbdH).